摘要
目的探讨小剂量尿激酶联合胞磷胆碱钠治疗脑干梗死的疗效。方法选取2010年1月—2013年6月于乐亭县中医医院神经内科住院的急性脑干梗死患者30例,结合患者及家属意愿将患者分为治疗组与对照组,各15例。治疗组予以尿激酶联合胞磷胆碱钠治疗治疗,对照组予以奥扎格雷钠治疗。观察两组患者脑卒中临床神经功能缺损程度评分(NIHSS)、临床疗效及不良反应发生情况。结果治疗前两组患者NIHSS评分比较,差异无统计学意义(P>0.05),治疗后24h、14d治疗组患者NIHSS评分低于对照组,差异有统计学意义(P<0.05);治疗组患者总有效率高于对照组(P<0.05);两组患者均未发生严重不良反应。结论小剂量尿激酶联合胞磷胆碱钠治疗脑干梗死的疗效显著,可改善患者预后,且不良反应小。
Objective To explore the effect of low dose urokinase and citicolin in treating brain stem infarction. Methods A total of 30 patients with brain stem infarction were selected in the Traditional Chinese Medicine Hospital of Leting County from January 2010 to June 2013,combined with the patient and family to intend,they were divided into treatment group and control group,15 cases in each group. Treatment group were given low dose urokinase and citicolin treatment, control group given sodium ozagrel treatment. NIHSS scores,clinical effect and incidence of adverse reactions between the two groups were compared. Results Before treatment,NIHSS scores showed no significant differences between the two groups（ P 〉0. 05）,24 hours after treatment and 14 days after treatment,NIHSS scores of the treatment group was lower than that of control group（P〈0. 05）;the total effective rate of treatment group was higher than that of control group（P〈0. 05）;no one of the two groups occurred serious adverse reactions. Conclusion Low dose urokinase and citicolin has notable curative effect in the treatment of brain stem infarction,can improve the prognosis of patients and is with less adverse reactions.
出处
《临床合理用药杂志》
2015年第15期7-8,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
脑干梗死
尿激酶型纤溶酶原激活物
胞磷胆碱钠
治疗结果
Brain stem infarction
Urokinase-type plasminogen activator
Citicoline sodium
Treatment outcome
